acquisitions– tag –

Strategic Overview: Otsuka’s Global Expansion in CNS and Rare Diseases Otsuka Pharmaceutical has focused heavily on the central nervous system (CNS), leveraging U.S.-centered M&A and partnerships to expand its product pipeline. In re...

Strategic Review: Global Expansion through ADC-Focused Oncology Partnerships Daiichi Sankyo has built a strong global presence through its antibody-drug conjugate (ADC) platform. While previous partnerships with AstraZeneca and Seagen we...

Strategic Review: Rare Disease, GI, Vaccines, and Innovation Takeda has transformed itself into a global biopharma leader through acquisitions such as Nycomed in 2011 (expanding GI/respiratory reach in Europe), Shire in 2018 (rare diseas...

Strategic Review: Antibody Innovation Meets Gene Editing and RNA Technology Regeneron Pharmaceuticals has leveraged its VelociSuite antibody platform to become a leader in ophthalmology, oncology, and immunology. Over the last decade, it...

Strategic Overview: Expanding from Diabetes to Obesity, RNA, and Cardiometabolic Disease Novo Nordisk, known for its leadership in GLP-1 receptor agonists (Ozempic, Wegovy), has expanded significantly over the past decade. Through acquis...

Strategic Review: Shifting from Antivirals to Oncology and Cell Therapy Gilead Sciences, once dominant in the antiviral space—particularly in HIV and hepatitis C—has been facing declining revenue due to patent cliffs. Since 2015, the com...

Strategic Review: Building a Cell and Gene Therapy Pipeline with BlueRock and AskBio Over the past decade, Bayer has transitioned from conventional pharmaceuticals into emerging modalities like gene editing, cell therapies, and regenerat...

Strategic Review: Diversifying into Oncology and Immunology Through Innovative Partnerships Boehringer Ingelheim (BI), traditionally strong in cardiovascular and respiratory areas, has pivoted towards oncology and immune diseases over th...

Key Pharma Moves: Sanofi’s Acquisitions and Collaborations in Q1–Q3 2025 In 2025, Sanofi has executed several key strategic acquisitions and licensing deals focused on immunology, neurology, and rare diseases. Here's a summary of these d...

Strategic Review: Diversifying Beyond Humira AbbVie has proactively diversified its portfolio beyond Humira, expanding into oncology, neuroscience, immunology, ophthalmology, and aesthetics. Its acquisition of Allergan, ADC platforms, an...

Strategic Review: From Opdivo to Next-Gen Modalities BMS is known as a pioneer in immuno-oncology, with the development of Opdivo (nivolumab) and Yervoy (ipilimumab). Over the past decade, the company has expanded aggressively into new m...

Strategic Review: Expanding from Monoclonal Antibodies into Diagnostics, RNA, and Cell Therapy Roche has long been a global leader in monoclonal antibody-based cancer therapies. Over the past decade, the company has strategically expande...

Strategic Review: Immunology, Oncology, and Rare Diseases at the Core of J&J’s R&D-Driven Vision Johnson & Johnson (J&J) has strategically expanded into immunology, oncology, and rare diseases by acquiring biotech compani...